Approaches to a long-acting, selective beta 2-adrenoceptor stimulant.
Selected beta 2-stimulants were sought that would stick more firmly than salbutamol at their sites of action on the beta 2-adrenoceptor protein in the cell membrane. Of the substance synthesized and tested it was concluded that salmeterol represented a new class of beta 2-stimulants that because of their exceptionally long duration of action have potential clinical advantages over current available beta 2-stimulants in the treatment of asthma.
Brittain
R T
RT
Glaxo Group Research, Ltd., Ware, Hertfordshire, United Kingdom.
D000318:Adrenergic beta-Agonists; D000403:Airway Resistance / Q000187:drug effects*; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D006168:Guinea Pigs; D006801:Humans; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations; D011943:Receptors, Adrenergic, beta; D000068299:Salmeterol Xinafoate; D000420:Albuterol